Breast Cancer Treatment: To tARget or Not? That Is the Question.
AR
CDK4/6
CYP17 lyase
DHT
ER
HER2
PI3K/AKT
PR
TNBC
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
received:
23
10
2023
revised:
27
11
2023
accepted:
27
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
To assess AR's role in TNBC treatment, various existing and completed clinical trials targeting AR or co-targeting AR with other pertinent signaling molecules were analyzed. Cyclin-dependent kinase 4/6 (CDK4/6), cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17 lyase), and the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway were some of the most prevalent biomarkers used in combination therapy with AR inhibitors in these trials. Studying how AR functions in tandem with these molecules can have increasing breakthroughs in the treatment options for TNBC. Previous studies have been largely unsuccessful in utilizing AR as the sole drug target for systemic targeted treatment in TNBC. However, there is a lack of other commonly used drug target biomarkers in the treatment of this disease, as well. Thus, analyzing the clinical benefit rate (CBR) within clinical trials that use combination therapy can prove to be imperative to the progression of improving treatment options and prognoses.
Identifiants
pubmed: 38067367
pii: cancers15235664
doi: 10.3390/cancers15235664
pmc: PMC10705204
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R21CA260381
Pays : United States
Références
Cell Rep. 2016 Oct 18;17(4):966-976
pubmed: 27760327
Invest New Drugs. 2017 Feb;35(1):87-94
pubmed: 27826831
Oncotarget. 2015 Dec 8;6(39):41976-87
pubmed: 26506516
J Oncol Pharm Pract. 2019 Jan;25(1):110-129
pubmed: 29726787
NPJ Breast Cancer. 2020 Sep 25;6:47
pubmed: 33062889
Ther Adv Med Oncol. 2016 Jul;8(4):267-75
pubmed: 27482286
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Nat Commun. 2021 Nov 1;12(1):6276
pubmed: 34725325
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Cancer Treat Rev. 2010 May;36(3):206-15
pubmed: 20060649
Clin Cancer Res. 2011 Apr 1;17(7):1867-74
pubmed: 21325075
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Mol Oncol. 2022 Jul;16(14):2632-2657
pubmed: 34967509
Front Endocrinol (Lausanne). 2020 Feb 11;11:35
pubmed: 32117061
PLoS One. 2022 Dec 22;17(12):e0279522
pubmed: 36548336
Clin Breast Cancer. 2022 Apr;22(3):269-278
pubmed: 34824002
J Clin Invest. 2017 Jun 1;127(6):2326-2338
pubmed: 28463227
Int J Oncol. 2020 Dec;57(6):1245-1261
pubmed: 33174058
N Engl J Med. 2022 Jul 21;387(3):217-226
pubmed: 35857659
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597
pubmed: 34848822
Onco Targets Ther. 2018 Aug 29;11:5253-5259
pubmed: 30214230
Am J Cancer Res. 2021 May 15;11(5):1913-1935
pubmed: 34094661
Cancer Chemother Pharmacol. 2019 Oct;84(4):759-770
pubmed: 31367790
J Intern Med. 2013 Aug;274(2):113-26
pubmed: 23844915
Steroids. 2015 Mar;95:80-7
pubmed: 25560485
Cancer Discov. 2016 Jul;6(7):740-53
pubmed: 27217383
PLoS One. 2017 Dec 20;12(12):e0189007
pubmed: 29261702
J Steroid Biochem Mol Biol. 2015 Jul;151:52-65
pubmed: 25482340
Breast Cancer (Dove Med Press). 2014 Aug 04;6:123-33
pubmed: 25177151
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Ther Adv Med Oncol. 2014 Jul;6(4):154-66
pubmed: 25057302
Biomed Res Int. 2019 Jul 4;2019:7201562
pubmed: 31355278
Clin Cancer Res. 2020 May 1;26(9):2111-2123
pubmed: 31822498
Breast Cancer Res. 2014 Aug 08;16(4):406
pubmed: 25103565
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Molecules. 2020 Jan 15;25(2):
pubmed: 31952272
Oncotarget. 2018 May 29;9(41):26406-26416
pubmed: 29899867
Nat Med. 2021 Feb;27(2):310-320
pubmed: 33462444
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
NPJ Breast Cancer. 2022 Mar 24;8(1):40
pubmed: 35332167
Biomolecules. 2022 Jan 04;12(1):
pubmed: 35053220
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Endocr Relat Cancer. 2015 Apr;22(2):249-64
pubmed: 25691442
Nat Rev Urol. 2014 Jan;11(1):32-42
pubmed: 24276076
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
JAMA Oncol. 2017 Sep 01;3(9):1266-1273
pubmed: 28301631